# US 2020/0206178 A1 · Esters for treatment of ocular inflammatory conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0206178 A1
- Document ID: US20200206178A1
- Status: Published application
- Kind: A1
- Application number: 16/789,793
- Filed: 2020-02-13
- Published: 2020-07-02
- Earliest claimed: 2011-06-30
- Assignees: Johnson & Johnson Vision Care, Inc.
- Applicants: Johnson & Johnson Vision Care, Inc.
- Inventors: Annabelle Gallois-Bernos
- Web page: https://patentgrep.com/patent/US20200206178A1

## CPC

- A61K 31/232: having three or more double bonds, e.g. etretinate
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 31/201: having one or two double bonds, e.g. oleic, linoleic acids
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/203: Retinoic acids {; Salts thereof}
- A61K 31/215: of carboxylic acids
- A61K 31/557: Eicosanoids, e.g. leukotrienes {or prostaglandins}
- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61K 31/683: Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 27/04: Artificial tears; Irrigation solutions
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. Anti-inflammatory lipid mediators can be selected from the group consisting of polyunsaturated fatty acids (e.g., omega-three and omega-six fatty acids), resolvins or a metabolically stable analog, protectins or a metabolically stable analog, lipoxins or a metabolically stable analog, prostaglandins or a metabolically stable analog, retinoic acids, endocannabinoids, metabolites thereof, and mixtures thereof. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.

## Claims

### Claim 1

An ophthalmic composition for treatment of ocular conditions, the composition comprising
an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol having a chain length of four to ten carbons; and
an aqueous delivery system;
wherein the composition is substantially free from acid.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the ester is present in a therapeutically effective amount.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the composition is substantially free of fatty acids.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the composition comprises 10% by weight or less of the acid form of the anti-inflammatory lipid mediator.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the composition comprises 5% by weight or less of the acid form of the anti-inflammatory lipid mediator.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the composition comprises 1% by weight or less of the acid form of the anti-inflammatory lipid mediator.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the ester is present in an amount in the range of about 0.01% to 5.0% by weight, based on the total composition.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the ester is present in an amount in the range of about 0.025% to 0.5% by weight, based on the total composition.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the ester is selected from the group consisting of an esterified polyunsaturated fatty acid, an esterified resolvin or its metabolically stable analog, an esterified protectin or its metabolically stable analog, an esterified lipoxin or its metabolically stable analog, an esterified prostaglandin or its metabolically stable analog, an esterified retinoic acid, metabolites thereof, an endocannabinoid, a phospholipid that comprises the residue of at least one omega-3 fatty acid, and mixtures thereof.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the anti-inflammatory lipid mediator is a prostaglandin selected from the group consisting of prostaglandin E1 (PGE1), prostaglandin E3 (PGE3), or a metabolically stable analog, and combinations thereof.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the anti-inflammatory lipid mediator is a resolvin selected from the group consisting of resolvin E1 (RvE1), resolvin E2 (RvE2), resolvin D1 (RvD1), resolvin D2 (RvD2), resolvin D3 (RvD3), resolvin D4 (RvD4), or a metabolically stable analog, and combinations thereof.

### Claim 12 (depends on 1)

The composition of claim 1, wherein the anti-inflammatory lipid mediator is a lipoxin selected from the group consisting of lipoxin A4 (LXA),lipoxin B4 (LXB4), or a metabolically stable analog, and combinations thereof.

### Claim 13 (depends on 1)

The composition of claim 1, wherein the anti-inflammatory lipid mediator comprises protectin D1 (PD1) or a metabolically stable analog.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the anti-inflammatory lipid mediator comprises 13-cis-retinoic acid.

### Claim 15 (depends on 5)

The composition of claim 5, wherein the anti-inflammatory lipid mediator comprises anandamide.

### Claim 16 (depends on 1)

The composition of claim 1, wherein the anti-inflammatory lipid mediator comprises at least one omega-three fatty acid selected from the group consisting of: alpha-linolenic acid, stearidonic acid, eicosatetraenoic acid, eicosapentaenoic acid, docohexaenoic acid (DHA), docosapentaenoic acid (DPA), tetracosapentaenoic acid, and tetracosahexaenoic acid (Nisinic acid), derivatives, metabolites, and mixtures thereof.

### Claim 17 (depends on 1)

The composition of claim 1, wherein the ester comprises esterified alpha-linolenic acid.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the esterified alpha-linolenic acid is present in an amount in the range of about 0.01% to 5.0% by weight, based on the total composition.

### Claim 19 (depends on 17)

The composition of claim 17, wherein the esterified alpha-linolenic acid is alpha-linolenic acid ethyl ester.

### Claim 20 (depends on 19)

The composition of claim 19, wherein the composition comprises, by weight of the composition:
the alpha-linolenic acid ethyl ester in an amount in the range of about 0.025to 5.0%;
a wetting agent that is methyl gluceth-20 in an amount in the range of about 0.025 to 5.0%;
a surfactant that is polysorbate 80 in an amount in the range of about 0.025 to 5.0%;
an antioxidant that is Vitamin E in an amount in the range of about 0.01to 0.1%; and
a water-based packing solution that optionally comprises one or more of a salt, a preservative, and a buffer.

### Claim 21 (depends on 1)

The composition of claim 1, wherein the aqueous delivery system comprises one or more of the following: a surfactant, an emulsifier, a wetting agent, a chelant, and an antioxidant.

### Claim 22 (depends on 1)

The composition of claim 1, wherein the aqueous delivery system comprises one or more ingredients selected from the group consisting of polysorbate 80™, Tyloxapol™, methyl gluceth-20, Vitamin E, diethylenetriaminepentaacetic acid, boric acid, sodium borate, and sodium chloride.

### Claim 23 (depends on 1)

The composition of claim 1, wherein the polyol is selected from the group consisting of polyethylene glycol, polyvinyl alcohol, inositol, sorbitol, xylitol, erythritol, and combinations thereof.

### Claim 24 (depends on 1)

The composition of claim 1, wherein the ester has the structure:
CH3—CH2—CH═CH—(CH2—CH═CH)n—(CH2)x—CO—O—R
or the amide has the structure:
CH3—CH2—CH═CH-(CH2—CH═CH)n-(CH2)x-CO—NH—R
wherein
n is 2, 3, 4, or 5;
x is 2, 3, 4, 5, 6, or 7;
R is an ophthalmologically compatible leaving group, including —(CH2)y—CH3, where y is 0 or greater.

### Claim 25 (depends on 24)

The composition of claim 24, wherein y is 1.

### Claim 26 (depends on 1)

The composition of claim 1, wherein the anti-inflammatory lipid mediator comprises an omega-three fatty acid, an omega-six fatty acid, or both.

### Claim 27 (depends on 26)

The composition of claim 26, wherein
the omega-three fatty acid is selected from the group consisting of: alpha-linolenic acid, stearidonic acid, eicosatetraenoic acid, eicosapentaenoic acid, docohexaenoic acid (DHA), docosapentaenoic acid (DPA), tetracosapentaenoic acid, and tetracosahexaenoic acid (Nisinic acid), derivatives, metabolites, and mixtures thereof; and
the omega-six fatty acid is selected from the group consisting of linoleic acid, gamma-linolenic acid (GLA), eicosadienoic acid, dihomo-gamma-linolenic acid (DGLA), docosadienoic acid, adrenic acid, docosapentaenoic acid, or combinations thereof.

### Claim 28 (depends on 1)

The composition of claim 1, wherein the ester is the reaction product of a fatty acid and an amine to form an amidoester.

### Claim 29 (depends on 1)

A sterile preparation, solution, gel, ointment, emulsion or strip for administration to the eye or a contact lens comprising the composition of claim 1.

### Claim 30 (depends on 1)

A method of preparing an ophthalmic composition for treatment of ocular conditions, the method comprising providing the composition of claim 1 and forming the ophthalmic composition.

### Claim 31 (depends on 1)

A method of preventing inflammatory ocular conditions, dry-eye, or both in an individual in need thereof which comprises delivering a therapeutically effective amount of a composition according to claim 1 to the individual's ocular surface.

### Claim 32 (depends on 31)

The method of claim 31 wherein the concentration of the ester in the composition is in the range of 0.025 weight % to 5.0 weight %.

### Claim 33 (depends on 1, 31)

The method of claim 31 wherein the delivery step comprises administering eye drops comprising the composition of claim 1.

### Claim 34 (depends on 31)

The method of claim 31 wherein the delivery step comprises positioning a contact lens on the ocular surface, wherein the contact lens was soaked or hydrated in the composition.

### Claim 35 (depends on 1)

A method of relieving dry-eye symptoms comprising administering a therapeutically effective amount of the composition of claim 1 to relieve at least one eye of a patient suffering from said symptoms.

### Claim 36 (depends on 1)

A method of mitigating dry eye symptoms comprising administering a therapeutically effective amount of the composition of claim 1 to at least one eye of a patient suffering from said symptoms.

### Claim 37

A method of treating an eye condition comprising delivering, from an ophthalmic device, a therapeutically effective amount of an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol to at least one eye suffering in need of therapy for dry eye, meibomian gland dysfunction, blepharitis, atopic keratoconjunctivitis, contact lens-related dry eye, Sjögren's syndrome, uveitis, macular degeneration, and combinations thereof.

### Claim 38 (depends on 37)

The method of claim 37, wherein the ophthalmic device is a contact lens.

### Claim 39 (depends on 37)

The method of claim 37, wherein the ester is selected from the group consisting of an esterified polyunsaturated fatty acid, an esterified resolvin or its metabolically stable analog, an esterified protectin or its metabolically stable analog, an esterified lipoxin or its metabolically stable analog, an esterified prostaglandin or its metabolically stable analog, an esterified retinoic acid, an endocannabinoid, metabolites thereof, and mixtures thereof.

### Claim 40 (depends on 1)

The composition of claim 1, wherein the ester is the reaction product of a fatty acid and polyethylene glycol to form an ethoxylate.

### Claim 41 (depends on 1)

The composition of claim 1, wherein the ester is the reaction product of a fatty acid and polyvinyl alcohol to form an alkoxylate.

### Claim 42 (depends on 1)

A sterile preparation, solution, gel, ointment, emulsion or strip for administration to the eye or a contact lens comprising the composition of claim 1.

### Claim 43 (depends on 1)

A method of preparing an ophthalmic composition for treatment of ocular conditions, the method comprising providing the composition of claim 1 and forming the ophthalmic composition.

### Claim 44 (depends on 1)

A method of combating inflammatory ocular conditions, dry-eye, or both in an individual in need thereof which comprises delivering a therapeutically effective amount of a composition according to claim 1 to the individual's ocular surface.

### Claim 45 (depends on 1)

A method of providing osmoprotection comprising using the composition of claim 1 to provide osmoprotection to an individual's ocular surface.
